Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2007
04/19/2007WO2007042239A1 Prolinamide derivatives as sodium channel modulators
04/19/2007WO2007042178A1 Diacyl indazol derivatives as lipase and phospholipase inhibitors
04/19/2007WO2007042146A1 Microangiopathy treatment and prevention
04/19/2007WO2007042111A2 Use of estradiol valerate combined with dienogest for oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
04/19/2007WO2007042110A1 Method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding
04/19/2007WO2007042048A2 Method for preparing crystalline sodium risedronate
04/19/2007WO2007042037A1 Tacrolimus combination products
04/19/2007WO2007042035A2 Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
04/19/2007WO2007042034A1 Controlled release pharmaceutical compositions comprising a fumaric acid ester
04/19/2007WO2007042010A2 Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids
04/19/2007WO2007041986A1 Antimitotic rhizoxin derivatives of burkholderia rhizoxina, method for producing said derivatives and use thereof
04/19/2007WO2007041965A1 The application of trpc in screening anti-tumor medicaments and the pharmaceutical use of its inhibitor
04/19/2007WO2007041951A1 Extraction method of abalone polysaccharide
04/19/2007WO2007041950A1 Extraction method of patinopecten yessoensis polysaccharide
04/19/2007WO2007041936A1 Alkyl alcohol piperazine derivative optical isomers and their salts and applications thereof
04/19/2007WO2007041868A1 Method for detecting a biomarker of oxidative stress in a biological sample
04/19/2007WO2007041863A1 Method for treating neuronal and non-neuronal pain
04/19/2007WO2007041855A1 Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
04/19/2007WO2007041842A1 An inflammatory mediator of cardiac adrenergic dysfunction
04/19/2007WO2007041837A1 Cathepsin cysteine protease inhibitors
04/19/2007WO2007041833A1 Combined use of dpp iv inhibitors and gastrin compounds
04/19/2007WO2007041832A1 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
04/19/2007WO2007041790A1 Salts of proton pump inhibitors and process for preparing same
04/19/2007WO2007041775A1 Cysteine protease inhibitors incorporating azide groups
04/19/2007WO2007041772A1 Preparation for the treatment of diarrhoea
04/19/2007WO2007025994A3 Use of at least one 2-alkyl furan, as depigmenting or lightening active principle
04/19/2007WO2007025632A3 Nitrooxy derivatives op glucocorticoids
04/19/2007WO2007025055A3 Benztropine compounds and uses thereof as dopamine uptake inhibitors
04/19/2007WO2007021189A3 Method of treating parturient placental mammals in order to reduce maternal and/or utirine exhaustion
04/19/2007WO2007020013A3 Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
04/19/2007WO2007019440A3 Method for producing l-carnitine or acetyl-l- carnitine from germinating seeds
04/19/2007WO2007019251A9 Sphingosine kinase inhibitors and methods of their use
04/19/2007WO2007017895A3 Stabilized oral pharmaceutical compositions of cephalosporins
04/19/2007WO2007017758A3 Novel cysteine protease inhibitors and their therapeutic applications
04/19/2007WO2007017758A2 Novel cysteine protease inhibitors and their therapeutic applications
04/19/2007WO2007017646A3 Anti-malarial composition comprising artesunate and lumefantrine
04/19/2007WO2007017546A3 Method of obtaining tryptamine derivatives
04/19/2007WO2007017544A3 Method of obtaining 3,3-diphenylpropylamines
04/19/2007WO2007017127A3 Controlled realease dosage form of pirazole compounds to treat urinary incontinence
04/19/2007WO2007016153A3 Tilmicosin formulation
04/19/2007WO2007015923A3 Benzimidazoles useful as inhibitors of protein kinases
04/19/2007WO2007015270A3 Novel controlled release compositions of selective serotonin reuptake inhibitors
04/19/2007WO2007012870A3 Use of nefopam for the treatment of affective disorders
04/19/2007WO2007012539A3 Pharmaceutical formulation of nitrooxyderivatives of nsaids
04/19/2007WO2007011629A3 Synthesis and complete stereochemical assignment of psymberin/irciniastatin for anti-tumor use
04/19/2007WO2007010369A3 Sustained release formulation of alprazolam
04/19/2007WO2007009758A3 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist
04/19/2007WO2007009734A3 Combination preparation, particularly for treating prostate cancer
04/19/2007WO2007009707A3 Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
04/19/2007WO2007009704A3 Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
04/19/2007WO2007009656A3 Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
04/19/2007WO2007009389A3 Substituted propanamide derivatives, preparation and use thereof
04/19/2007WO2007009012A3 Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof
04/19/2007WO2007007152A3 Anti-madcam antibodies to treat metastatic cancers and chloroma
04/19/2007WO2007006797A8 Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer
04/19/2007WO2007006534A3 Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity
04/19/2007WO2007005887A3 Androgen receptor modulator compounds, compositions and uses thereof
04/19/2007WO2007005541A8 Small molecule inhibitors against west nile virus replication
04/19/2007WO2007004236A3 Improved drug or pharmaceutical compounds and a preparation thereof
04/19/2007WO2007003422A9 Crystalline forms of macrolide compounds endowed with antiinflammatory activity
04/19/2007WO2007003389A3 Substituted sulfolanyl pyrazoles and the use thereof
04/19/2007WO2007002897A8 Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for treatment of cardiovascular disease
04/19/2007WO2007002361A3 3-fluoro-piperidine t-type calcium channel antagonists
04/19/2007WO2007001684A9 Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
04/19/2007WO2007000339A8 Bicyclic derivatives as p38 kinase inhibitors
04/19/2007WO2007000337A8 Bicyclic derivatives as p38 kinase inhibitors
04/19/2007WO2007000325A3 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-on- compounds and the use thereof for producing drugs
04/19/2007WO2006138396A3 Methods for selective n-9 glycosylation of purines
04/19/2007WO2006136419A3 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
04/19/2007WO2006136408A3 Process for preparing pure amorphous rosuvastatin calcium
04/19/2007WO2006134021A3 Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
04/19/2007WO2006133837A3 A process for the preparation of an injectable solution of (2s)-n-(2;6-dimethyl-phenyl)-1-propyl-2-piperidincarboxamide
04/19/2007WO2006133199A3 Treatment with sigma receptor agonists post-stroke
04/19/2007WO2006131398A3 Inhibitors of soluble adenylate cyclase
04/19/2007WO2006131340A3 Pyrrolones that act as peptide deformylase (pdf) inhibitors
04/19/2007WO2006131322A3 Use op brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy
04/19/2007WO2006129859A3 Combinations of a squalene synthase inhibitor and a hmg-coa reductase inhibitor for treating hyperlipidemia
04/19/2007WO2006128693A3 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
04/19/2007WO2006128159A3 North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses
04/19/2007WO2006125813A3 Tetrahydropyridothiophenes for use in the treatment of cancer
04/19/2007WO2006125616A3 Pyrimidine-based cdk inhibitors for treating pain
04/19/2007WO2006123354B1 Oral pharmaceutical composition
04/19/2007WO2006123185A3 Sulphamides for treatment of cancer
04/19/2007WO2006123184A3 Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer
04/19/2007WO2006120176A3 Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
04/19/2007WO2006119160A3 Polymer conjugate enhanced bioassays
04/19/2007WO2006118973A3 Methods of using heterobyclic compounds for treatment of rectal cancer
04/19/2007WO2006117139A3 Solid transdermal therapeutic system comprising uv absorber
04/19/2007WO2006116157A3 Dipeptidyl peptidase-iv inhibitors
04/19/2007WO2006115413A3 Methods and means for the treatment of hpv induced intraepithelial neoplasias
04/19/2007WO2006112973A3 Treatment of schizophrenia using phosphodiesterase 5 inhibitors
04/19/2007WO2006111296A3 Dosage forms and combined preparations of pyrimidine biosynthesis inhibitors for achieving additional effects upon the immune system
04/19/2007WO2006110638A3 Inhibitors of akt activity
04/19/2007WO2006109170A3 Combination therapy for treatment of cardiovascular diseases and related conditions
04/19/2007WO2006105741B1 Topical pharmaceutical formulation containing nimesulide
04/19/2007WO2006099385A3 Stabilized compositions of volatile alkylating agents and methods of using thereof
04/19/2007WO2006086372A3 Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure
04/19/2007WO2006084041A3 Nitroxides for use in treating or preventing diabetes
04/19/2007WO2006083553A3 Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase
04/19/2007WO2006078942A3 Regulation of protein synthesis by inhibition of eif4e-eif4g interaction